Absci to Participate in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Absci (Nasdaq: ABSI) announced participation in three investor conferences in November 2025: a Guggenheim Securities fireside chat and 1x1 meetings on Nov 10, 2025 at 10:00 AM ET; UBS Global Healthcare 1x1 meetings on Nov 11, 2025; and a Jefferies Global Healthcare presentation and 1x1 meetings on Nov 18, 2025 at 9:30 AM GMT (4:30 AM ET).
Live and archived webcasts of the Guggenheim and Jefferies sessions will be available on Absci’s investor relations site at investors.absci.com.
Details
News Market Reaction – ABSI
On Oct 27, the day this news came out, ABSI closed 5.39% above the previous close.
Data tracked by StockTitan Argus for the Oct 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will be participating in the following upcoming investor conferences:
- Guggenheim Securities 2nd Annual Healthcare Innovation Conference (Boston, MA)
Fireside chat on Monday, November 10 at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time, and hosting 1x1 meetings
- UBS Global Healthcare Conference (Palm Beach Gardens, FL)
Hosting 1x1 meetings on Tuesday, November 11
- Jefferies Global Healthcare Conference (London, UK)
Presentation on Tuesday, November 18 at 9:30 a.m. Greenwich Mean Time / 4:30 a.m. Eastern Time, and hosting 1x1 meetings
Interested parties may access live and archived webcasts of the Guggenheim and Jefferies fireside chat and presentation sessions on the company’s investor relations website at investors.absci.com.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.